ARTELO BIOSCIENCES INC C/WTS 25/06/2024(TO PUR COM) ARTLW 深 沪
等待开盘 10-09 09:30:00 美东时间
0.0056
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0056
- 总市值 1.87万
- 52周最高 0.1498
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.005
- 委 比 0.00%
- 总股本 334.74万
- 历史最高 1.25
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.005
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Artelo Biosciences (ARTL) Stock Surges Wednesday: What's Happening?
Artelo Biosciences, Inc. (NASDAQ:ARTL) shares are surging Wednesday afternoon after the clinical-stage biopharmaceutical company announced the filing of a new provisional patent application covering its drug candidate ART27.13 for the treatment of obesity. The patent submission protects ART27.13 bot...
09-24 01:46
Artelo Biosciences shares are trading higher after the company announced the filing of a provisional patent application for ART27.13 as a monotherapy and in combination with GLP-1 receptor agonists.
Artelo Biosciences shares are trading higher after the company announced the filing of a provisional patent application for ART27.13 as a monotherapy and in combination with GLP-1 receptor agonists.
09-24 01:23
Artelo Biosciences shares are trading lower. The company reported nonclinical results showing its oral cannabinoid agonist ART27.13 cut body weight by about 20% in obese mice, matching semaglutide.
Artelo Biosciences shares are trading lower. The company reported nonclinical results showing its oral cannabinoid agonist ART27.13 cut body weight by about 20% in obese mice, matching semaglutide.
09-16 22:58
Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity
<p>Artelo Biosciences announced promising results from a study of ART27.13, an oral, once-daily dual cannabinoid receptor agonist, in obese mice. ART27.13 alone reduced body weight by approximately 20%, matching the weight loss achieved with semaglutide. When combined with semaglutide, weight loss doubled to around 40%. The study suggests ART27.13 may act as a "metabolic regulator," selectively modifying weight and fat loss in obese animals while...
09-16 11:30
Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Artelo Biosciences, Inc. (Nasdaq: ARTL) announced that CEO Gregory D. Gorgas will participate in the H.C. Wainwright 28th Annual Global Investment Conference on September 14-16, 2026, in New York City. The company’s presentation will be available on September 11, 2026, at 7:00 a.m. ET, and can be accessed via the provided link. Management will also engage in one-on-one meetings with investors during the conference. Artelo focuses on developing th...
09-08 13:00
Artelo Biosciences shares are trading lower after the company announced a 1-for-9 reverse stock split.
Artelo Biosciences shares are trading lower after the company announced a 1-for-9 reverse stock split.
08-28 01:06
Artelo Biosciences Announces 1-For-9 Reverse Stock Split, Effective August 31
Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced a 1-for-9 reverse stock sp...
08-27 20:03
Artelo Biosciences Announces Reverse Stock Split
Artelo Biosciences, Inc. announced a 1-for-9 reverse stock split to increase share price and improve marketability. The split will take effect on August 31, 2026, with the new CUSIP number 04301G805. Shareholders' ownership percentages remain unchanged, and fractional shares will be rounded up. Approximately 547,774 shares will be outstanding post-split. For details, review the Form 8-K filed August 27, 2026.
08-27 12:00
Artelo Biosciences Says USPTO Issues Notice Of Allowance For U.S. Patent Application Covering Intended Commercial Formulation Of ART27.13, Peripherally Selective Cannabinoid Agonist Currently In Phase 2 Studies
The Patent Claims are for the Intended Commercial Formulation of ART27.13 Expected to Extend Patent Protection for ART27.13 through 2041 SOLANA BEACH, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipi...
08-17 20:56
Artelo Biosciences Q2 EPS $(0.89) Up From $(16.83) YoY
Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(0.89) per share. This is a 94.71 percent increase over losses of $(16.83) per share from the same period last year.
08-13 20:21
